GC Pharm acquires approval of ‘Glargia’ referencing insulin glargine
GC Pharm(CEO Eun-Cheol Huh) announced on the 9th that the company acquired approval of ‘Glargia(insulin glargine),’ an antidiabetic biosimilar(bioequivalently tested) from the Ministry of Food and Drug Safety.
The original product of ‘Glargia’ is ‘Lantus’ developed by Sanofi, a multinational pha...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
